Company Overview and News
SINGAPORE (Sept 13): Ongoing trade war has led to reluctance of many big players to reinvest in Asian or emerging nations even in Europe, presenting opportunities for YTL, Executive Chairman Francis Yeoh said in a Bloomberg Television interview with Juliette Saly at a summit in Singapore.
2018-09-04 seekingalpha - 1
Mason Hawkins’ 13F portfolio value increased ~10% from $8.17B to $8.95B this quarter. The number of positions remained steady at 28.
SAH CEIX.WI SONC CMCSK SHL CABO BAMGF GE CNX.WI INFY UTX MAT GHC ATU SKHCF GOOGL RLGY INFY BAMKF BATRA PK LSXMB BATRK HCMLY CCV LSXMA CTL BATRR CCZ GOOG LLPFX SKHCY AGN AMR BEN BATRB BEL BIDU BAM CEIX VIPS GEC FWONB CMCSA SOFO FDX FWONA VSAT HCMLF CCV.CL FWONK GNE LSXMK SIMA CNX
(Aug 21): As the world’s largest cement maker sheds assets, billionaires and industrial conglomerates are lining up for LafargeHolcim Ltd’s US$2 billion-worth of Indonesian kilns. A domestic buyer may be the best (only?) option.
DB HLBZF HCMLY PTHIY 532538 UCLQF THYCY ULTRACEMCO HCMLF UCLQY 5233 PTHIF HDELY THYCF
SINGAPORE (Aug 17): LafargeHolcim Ltd’s sale of its Indonesian unit has drawn interest from Asian billionaires and regional rivals including Japan’s Taiheiyo Cement Corp, people with knowledge of the matter said.
HLBZF HCMLY HCMLF 5233 HDELY THYCF THYCY
India's Ambuja Cements Ltd posted a 27 percent growth in second-quarter profit on Wednesday, beating market estimates, helped by higher cement sales and lower expenses.
HCMLY 500425 HCMLF AMBUY AMBUJACEM
Profit booking and weak Asian cues pulled the market lower for the second consecutive session today after hitting a three-month high Wednesday. ITC, Reliance Industries, Infosys and select banking and financials stocks led the market down.
BAJAJ-AUTO 500325 HCMLY 500425 533150 RELIANCE TCHQY 532977 BHRQY AMBUJACEM 532755 532215 505200 532541 AMBUY AXISBANK RIGD HDFCBANK BHARTIARTL EICHERMOT RLNIY NIITTECH YESBANK ECQRY AXB IBN 532648 YYBKY HEXAWARE 532129 TECHM AXBKY 532454 AXBA ICICIBANK GODREJPROP HCMLF HDB 532174 500180 534809 PCJEWELLER
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET